Modest Contribution of Bradykinin to Blood Pressure Reduction by Sacubitril/Valsartan in Chronic Heart Failure

Circulation Heart Failure 2026 Open access

Read full text
Authors: Deepak K. Gupta, Lynne Warner Stevenson, Erica M. Garner, Christopher Maulion, Hui Nian, Patricia R. Wright, Adina F. Turcu, Shouzou Wei, Nancy Jeanne Brown
DOI: 10.1161/circheartfailure.125.014117
Cited by: 1
References: 45

Abstract

BACKGROUND: Symptomatic hypotension can limit sacubitril/valsartan therapy. Neprilysin inhibition may augment vasodilators, such as bradykinin. We hypothesized that bradykinin contributes to blood pressure (BP) lowering with sacubitril/valsartan in stable ambulatory patients with heart failure and reduced ejection fraction

Fields of Study & Subjects

Coagulation Bradykinin Polyphosphates and Angioedema Heart Failure Treatment and Management Neuropeptides and Animal Physiology

Publication details

Journal / source
Circulation Heart Failure
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
19
Issue
6
Pages
e014117–e014117
Publication date
24 April 2026
Language
EN